The Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Dapagliflozin, improves renal specific outcomes, especially urinary albumin-to-creatinine ratio (UACR) and may prevent diabetic kidney disease, as a per a study in ‘Diabetes Care ‘. The study was conducted in 17,160 patients to measure the change in baseline UACR and cardio-renal outcomes to the drug dapagliflozin at 6 months, 12 months, and yearly thereafter. All participants included in this study had type-2 diabetes, creatine clearance of >60mL/min and cardiovascular risk factors.

The following were the key findings:

• UACR improved from baseline to 4.0 years with dapagliflozin, compared with placebo across all UACR and estimated glomerular filtration rate (eGFR) categories.
• Cardiorenal outcome was improved with dapagliflozin in patients from subgroups of UACR ≥30 mg/g compared to placebo.

This study concludes that dapagliflozin demonstrable beneficial effect on UACR and renal-specific outcome across baseline UACR categories, including patients with normal albumin excretion. Furthermore, the results imply that dapagliflozin may also play a role in the prevention of diabetic kidney disease.